Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03088540 · OUTCOME

Duration of Response (DoR) Per IRC

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 73.5 months

What was measured

DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD (per RECIST 1.1) or death due to any cause, whichever occurred earlier.

Analysis population: FAS included all randomized participants. Participants with confirmed CR or PR only are reported here.

Groups in this outcome

Cemiplimab

Participants received cemiplimab monotherapy

Chemotherapy

Participants received platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cemiplimab151
Chemotherapy76

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cemiplimab24.1Not reported18.635.2Not reported
Chemotherapy5.9Not reported4.36.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        18.6
        upper Limit
        35.2
        value
        24.1
      2. group Id
        OG001
        lower Limit
        4.3
        upper Limit
        6.3
        value
        5.9
denoms
  1. counts
    1. group Id
      OG000
      value
      151
    2. group Id
      OG001
      value
      76
    units
    Participants
description
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD (per RECIST 1.1) or death due to any cause, whichever occurred earlier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received cemiplimab monotherapy
    id
    OG000
    title
    Cemiplimab
  2. description
    Participants received platinum-based doublet chemotherapy
    id
    OG001
    title
    Chemotherapy
param Type
MEDIAN
population Description
FAS included all randomized participants. Participants with confirmed CR or PR only are reported here.
reporting Status
POSTED
time Frame
Up to 73.5 months
title
Duration of Response (DoR) Per IRC
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice